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INTRODUCTION 
United States patent law and policy embrace an expansive 
scope for patent eligible subject matter in order to effectuate the 
Constitutional mandate “to promote the Progress of Science and 
useful Arts by securing for limited Times to . . . Inventors the 
exclusive Right to their . . . Discoveries.”1  Supreme Court 
precedent clearly articulates the minimal restraints on patent 
eligible subject matter: only inventors who seek to claim a natural 
law, natural phenomenon, abstract idea, or mental process should 
be barred at the threshold of the United States patent examination 
system.2  These minimal restraints, collectively referred to herein 
as the “Fundamental Principles Exception,” reflect the balance 
between policies of liberally encouraging innovation while 
preserving fundamental concepts, principles, and ideas for free and 
unfettered use by all.3 
Even a patent claim that recites a fundamental principle may be 
patent eligible so long as the claim as a whole is not drawn solely 
to the principle.4  The operative question under the Fundamental 
Principles Exception is whether the claim defines an application of 
the principle with sufficient particularity so as not to preempt all 
uses and implementations of the principle.5  If so, then the claim 
recites patent eligible subject matter and is not excludable under 
 
 1 U.S. CONST. art. I, § 8, cl. 8. 
 2 See, e.g., Diamond v. Diehr, 450 U.S. 175 (1981); Diamond v. Chakrabarty, 447 
U.S. 303 (1980); Parker v. Flook, 437 U.S. 584 (1978); Gottschalk v. Benson, 409 U.S. 
63 (1972). 
 3 When addressing the question of patent eligible subject matter, it is crucial to 
understand and remember that a determination of patent eligibility is made at the very 
beginning of the patent examination procedure and is analytically distinct from the 
rigorous statutory requirements of patentability.  While a patent may easily satisfy the 
eligibility test—it is meant to be a low bar for access to the system—it must still satisfy 
the requirements of novelty, nonobviousness, enablement, etc., before a patent eligible 
claim is determined to be a patentable claim.  Patent eligibility must not be confused with 
patentability. 
 4 See In re Bilski, 545 F.3d 943, 953 (Fed. Cir. 2008) (en banc), cert. granted sub 
nom. Bilski v. Doll, 129 S. Ct. 2735 (2009), argued sub nom. Bilski v. Kappos, No. 08-
964, 2009 WL 3750776 (Nov. 9, 2009). 
 5 See Diehr, 450 U.S. at 203; see also Parker, 437 U.S. at 599; Gottschalk, 409 U.S. 
at 71; Bilski, 545 F.3d at 1011 (Rader, J., dissenting). 
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the Fundamental Principles Exception.  In In re Bilski,6 the Federal 
Circuit disparaged this inquiry as “hardly straightforward” and 
articulated the proxy “machine-or-transformation” test as the sole 
and definitive test to determine patent eligibility of process 
claims.7  Under that test, the operative questions are whether the 
claimed process is tied to a particular machine or apparatus or 
whether it transforms a particular article into a different state or 
thing.8  In either case, the particular machine or transformation also 
must “impose meaningful limits on the claim’s scope” and must 
not involve “insignificant extra-solution activity” or “mere data-
gathering” to “impart patent eligibility.”9 
While the Federal Circuit’s Bilski decision restricts business 
method patents, there is apprehension in the intellectual property 
community that the machine-or-transformation test will unfairly 
limit patents in the life sciences, particularly claims directed to 
diagnostic and screening methods.10  Having taken up Bilski on 
certiorari, the Supreme Court is poised to settle the question 
whether the machine-or-transformation test is the exclusive, 
mandatory test for patent eligibility of processes under 35 U.S.C. § 
101.  In our view, the Court should answer the question in the 
negative and reemphasize the Fundamental Principles Exception as 
the governing test because it is, contrary to the Federal Circuit’s 
characterization, straightforward and more likely to lead to a sound 
result than the highly subjective and complicated machine-or-
 
 6 545 F.3d 943 (Fed. Cir. 2008) (en banc), cert. granted sub nom. Bilski v. Doll, 129 
S. Ct. 2735 (2009), argued sub nom. Bilski v. Kappos, No. 08-964, 2009 WL 3750776 
(Nov. 9, 2009). 
 7 Id. at 954. 
 8 Id. 
 9 Id. at 961–62. 
 10 See Christopher Holman, Bilski: Assessing the Impact of a Newly Invigorated Patent 
Eligibility Doctrine on the Pharmaceutical Industry and the Future of Personalized 
Medicine, CURRENT TOPICS MED. CHEMISTRY (forthcoming) (manuscript at 18), available 
at http://ssrn.com/abstract=1424493; Matthew Ward & Jack Redfern, US Patent Law: No 
Longer Concrete, Tangible and Useful, MONDAQ, Mar. 30, 2009, http://www.mondaq. 
com/unitedstates/article.asp?articleid=77112. See generally Michael R. Samardzija, 
Recent Patent Rulings Can Impede the Progress of Personalized Medicine: The Bilski 
and Classen Decisions Can Render Numerous in Vitro Diagnostic Claims Unpatentable, 
BIOPHARM INT’L, Aug. 2009, at 2, 2, available at http://biopharminternational.find 
pharma.com/biopharm/Business+Articles/Recent-Patent-Rulings-Can-Impede-the-
Progress-of-P/ArticleStandard/Article/detail/615147. 
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transformation test.  The Fundamental Principles Exception is a 
broader, more flexible test to determine the threshold question of 
patent eligibility, which is consistent with well-settled law and 
public policy.  In Part I of this article, we briefly survey the law 
and policy that supports a broad, flexible test to determine patent 
eligibility.  In Part II, starting with the important Laboratory Corp. 
of America Holdings v. Metabolite Laboratories, Inc. 
(“LabCorp”)11 case, we analyze patent eligibility of personalized 
medicine patent claims at issue in recent cases and contrast the 
limitations of the machine-or-transformation test against the 
simpler, more flexible approach of the Fundamental Principles 
Exception.  We conclude that while the machine-or-transformation 
test may be a useful way to assess certain types of inventions, it 
should not be the mandatory, exclusive test for determining patent 
eligibility of process patents.  
I. THE LAW AND POLICY SUPPORTING A BROAD, FLEXIBLE TEST 
FOR PATENT ELIGIBILITY 
As Judge Rader so aptly noted in his dissent in Bilski, one of 
our founding fathers, Thomas Jefferson, articulated the policy 
underpinning the Patent Copyright Clause12 of the Constitution: 
“Nobody wishes more than I do ingenuity should receive a liberal 
encouragement.”13  Mr. Jefferson recognized the importance of 
commercial incentives attendant patent exclusivity as a sharp spur 
to innovation and progress in the sciences and useful arts.  The 
liberal encouragement of ingenuity and innovation intended to be 
fostered by the grant of exclusive patent rights was reflected in the 
 
 11 548 U.S. 124 (2006). 
 12 U.S. CONST. art. I, § 8, cl. 8. 
 13 5 WRITINGS OF THOMAS JEFFERSON 75–76 (Washington ed. 1871); see also Bilski, 
545 F.3d at 1011 (Rader, J., dissenting) (“The Patent Law of the United States has always 
embodied the philosophy that ‘ingenuity should receive a liberal encouragement.’” 
(quoting WRITINGS OF THOMAS JEFFERSON, supra, at 75–76)).  Mr. Jefferson also 
recognized the danger of overprotection of patent rights, noting the difficulty of 
“‘drawing a line between the things which are worth to the public the embarrassment of 
an exclusive patent, and those which are not.’” Graham v. John Deere Co., 383 U.S. 1, 9 
(1966) (citing Letter from Thomas Jefferson to Isaac McPherson (Aug. 13, 1813), 
reprinted in 13 THE WRITINGS OF THOMAS JEFFERSON 326, 334 (Andrew A. Lipscomb & 
Albert Ellery Bergh eds., 1905)). 
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almost boundless language of the Constitution that provides for the 
time-limited, exclusive right of inventors to their “Discoveries.”14  
In the case of patent eligibility for process or method claims, the 
language of 35 U.S.C. § 101 is broad and clear: “any new and 
useful process” or “any new and useful improvement thereof” is 
patent eligible.15  Therefore, any new process that has practical 
utility and is not excludable under the Fundamental Principles 
Exception is patent eligible and entitled to examination for 
compliance with patentability requirements. 
In Diamond v. Diehr,16 the Supreme Court articulated that a 
process claim which includes a fundamental principle is patent 
eligible as long as the process as a whole represents “an 
application of a law of nature or mathematical formula.”17  In 
Diehr, the invention under consideration was a physical and 
chemical process for molding precision synthetic rubber products, 
where the claimed process steps included the use of a mathematical 
formula.18  The Court cautioned against reading limitations into the 
patent laws not expressed by the legislature19 and went on to 
clarify that in a case where an inventor discovered a previously 
unknown natural law or phenomenon (more recently exemplified 
in the diagnostic method claimed in the LabCorp20 case): “‘[i]f 
there is to be invention from such a discovery, it must come from 
the application of the law of nature to a new and useful end.’”21  
 
 14 U.S. CONST. art. I, § 8, cl. 8.  While discoveries arguably include natural laws and 
phenomena, it always has been understood that patent eligible discoveries include 
“anything under the sun that is made by man.” Diamond v. Chakrabarty, 447 U.S. 303, 
309 (1980) (emphasis added) (quoting S. REP. NO. 82-1979, at 5 (1952), reprinted in 
1952 U.S.C.C.A.N. 2394, 2399; H.R. REP. NO. 82-1923, at 6 (1952)).  Citing a long line 
of precedent, the Court noted that “laws of nature, physical phenomena, and abstract 
ideas have been held not patentable.” Id.  Even though the dividing line between patent 
eligible inventions and ineligible fundamental principles is, of course, sometimes quite 
difficult to draw, the Supreme Court consistently has adhered to that broad flexible 
standard and refused to restrict patent eligibility by imposing a more limited, rigid test. 
15  35 U.S.C. § 101 (2006).  
 16 450 U.S. 175 (1981). 
 17 Id. at 187. 
 18 Id. at 177. 
 19 Id. at 182. 
 20 Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 548 U.S. 124, 125 (2006). 
 21 Diehr, 450 U.S. at 188 n.11 (quoting Funk Bros. Seed Co. v. Kalo Inoculant Co., 
333 U.S. 127, 130 (1948)). 
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The Court distinguished a claim that, as a whole, would preempt 
all uses of a mathematical formula—a patent ineligible abstract 
idea—from the claim at issue in Diehr, which applied a 
mathematical formula for a particular use: 
[W]hen a claim containing a mathematical formula 
implements or applies that formula in a structure or 
process which, when considered as a whole, is 
performing a function which the patent laws were 
designed to protect (e.g., transforming or reducing 
an article to a different state or thing), then the 
claim satisfies the requirements of § 101.22 
The takeaway, in short, is that a process or method claim is 
patent eligible if, when considered as a whole, it defines an 
application of a fundamental principle with sufficient particularity 
so as not to preempt all uses and implementations of the principle. 
The policies of promoting the progress of science and useful 
technologies, liberally encouraging innovation and ingenuity, 
maintaining a strong patent system, and helping to sustain 
emerging industries and long-term job growth all support well-
settled Supreme Court precedent articulating process patent 
eligibility requirements.  A broad, flexible test, as embodied in the 
Fundamental Principles Exception, encourages inventors and 
investors alike to commit significant human and financial capital to 
research and development efforts in many different fields.  This is 
particularly true in the emerging fields of medical and genetic 
diagnostics.  Although estimates vary widely, it can cost hundreds 
of millions of dollars and take more than ten years to develop a 
 
 22 Id. at 192.  As noted in Judge Newman’s dissent in Bilski, the use of the exemplary 
“e.g.” in the parenthetical contradicts the majority’s determination that “machine-or-
transformation” is the definitive, mandatory test for assessing patent eligibility. In re 
Bilski, 545 F.3d 943, 982 (Fed. Cir. 2008) (en banc) (Newman, J., dissenting), cert. 
granted sub nom. Bilski v. Doll, 129 S. Ct. 2735 (2009), argued sub nom. Bilski v. 
Kappos, No. 08-964, 2009 WL 3750776 (Nov. 9, 2009); see also Parker v. Flook, 437 
U.S. 584, 589 n.9 (1978) (“The statutory definition of ‘process’ is broad.  An argument 
can be made, however, that this Court has only recognized a process as within the 
statutory definition when it either was tied to a particular apparatus or operated to change 
materials to a ‘different state or thing.’  As in Benson, we assume that a valid process 
patent may issue even if it does not meet one of these qualifications of our earlier 
precedents.” (internal citations omitted)).  
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successful biologic drug or genetic screening test.23  Broad access 
to the patent system, to the fullest extent permitted under the 
Constitution and without limitations that have not been expressed 
by Congress, is crucial to the support of these emerging 
technologies. 
II. PATENT ELIGIBILITY OF DIAGNOSTIC METHODS AND OTHER 
PERSONALIZED MEDICINE INVENTIONS 
A. The LabCorp Case 
Accurate and early diagnosis of cobalamin (Vitamin B12) and 
folate deficiencies in humans is important because these vitamin 
deficiencies can lead to serious, potentially life-threatening, blood 
and neuropsychiatric disorders.24  The university researchers who 
obtained and enforced the diagnostic method claims at issue in 
LabCorp, were conducting research to develop an improved assay 
(test) for cobalamin and folate deficiencies.25  The inventors 
discovered that there were abnormally high homocysteine26 levels 
in the blood of patients who suffered from cobalamin and/or folate 
deficiencies, a specific biochemical correlation that was previously 
unknown.27  The inventors used this discovery to develop a new 
and better test for diagnosing cobalamin and folate deficiencies.28 
The inventors’ patent contains several different method claims 
that cover new methods for conducting the homocysteine assay 
itself, for example by using a labeled reference standard and mass 
spectrometer in a process to determine homocysteine levels (claims 
 
 23 See, e.g., Nathan Koppel, Genetic Research Spurs Fight over Patents Tied to the 
Body, WALL ST. J., Dec. 10, 2009, at A21. 
 24 U.S. Patent No. 4,940,658 col. 1 ll. 32–40 (filed Nov. 20, 1986) (issued July 10, 
1990).   
 25 See Lab. Corp., 548 U.S. at 125–28. 
 26 Homocysteine is a particular species of amino acid known as a “sulfhydryl amino 
acid.” Pål I. Holm et al., Modulation of the Homocysteine-Betaine Relationship by 
Methylenetetrahydrofolate Reductase 677 C->T Genotypes and B-Vitamin Status in a 
Large-Scale Epidemiological Study, 92 J. CLINICAL ENDOCRINOLOGY & METABOLISM 
1535, 1535 (2007).  
 27 See Lab. Corp., 548 U.S. at 128. 
 28 Id. 
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1 and 7).29  The patent eligibility of these method claims for 
determining homocysteine levels was not challenged because they 
represent a classic, practical application—improving the process of 
measuring homocysteine—derived from the newly discovered 
naturally occurring correlation between elevated homocysteine 
levels and cobalamin or folate deficiencies.30  The patent also 
includes a series of diagnostic claims for a method of detecting a 
cobalamin or folate deficiency.31  Independent claim 1332 reads as 
follows: “[a] method for detecting a deficiency of cobalamin or 
folate in warm-blooded animals comprising the steps of: assaying 
a body fluid for an elevated level of total homocysteine; and 
correlating an elevated level of total homocysteine in said body 
fluid with a deficiency of cobalamin or folate.”33 
A medical diagnostic process claim of this type is characterized 
by a data determination step, which identifies or measures a 
biological or chemical marker, followed by a mental step of a 
physician or medical practitioner who utilizes the information 
obtained in the first step to infer or recognize the newly discovered 
phenomenon and diagnose the patient.34  Though admittedly broad, 
claim 13 may well define a patent eligible process when assessed 
under the Fundamental Principles Exception, notwithstanding 
Justice Breyer’s conclusion to the contrary.35  A close examination, 
 
 29 Id.; ’658 Patent col. 41 ll. 2–19, 34–35. 
 30 Id.; see also John A. O’Brien, Bilski v. Doll—Is the Federal Circuit’s “Machine or 
Transformation” Test the Only Test for § 101 Subject Matter?, 977 PLI/Pat 437, 447 
(2009). 
 31 Lab. Corp., 548 U.S. at 129. 
 32 We note that the petition for certiorari in LabCorp was dismissed as improvidently 
granted because LabCorp had failed to raise the § 101 challenge to claim 13 below. See 
id. at 125–26. 
 33 ’658 Patent col. 41 ll. 58–65 (emphasis added). 
 34 This type of diagnostic method has been coined a “determine-and-infer” claim. See 
Kevin E. Collins, An Initial Comment on Prometheus: The Irrelevance of Intangibility, 
PATENTLY-O, Sept. 17, 2009, at 2, http://www.patentlyo.com/collins.intangibility.pdf.  
Determine-and-infer claims provide powerful commercial incentives for innovation 
because they broadly convey exclusive rights to new, useful, and nonobvious processes 
involving recognition of previously unknown biochemical or genetic correlations, 
metabolic pathways or similar natural phenomena that are highly useful for diagnosing, 
treating and preventing disease. See id. at 5–8.  These are precisely the kind of incentives 
that drive capital-intensive innovation in emerging technologies. See id.  
 35 See Lab. Corp., 548 U.S. at 134–38 (Breyer, J., dissenting). 
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however, does reveal the potential for confusion and inconsistent 
results that may arise depending on the analytical test used to 
assess patent eligibility. 
1. Well-Settled Fundamental Principles Analysis 
Applying the Fundamental Principles Exception to LabCorp 
claim 13, the pertinent question is: does the claim as a whole 
define an application of the correlation between elevated 
homocysteine and deficient cobalamin/folate with sufficient 
particularity so as not to preempt substantially all uses and 
implementations of the correlation? 
Using this analytical test, the patent eligibility of claim 13 
becomes clearer.  As so aptly noted by Judge Rader in his Bilski 
dissent: 
The fundamental error in that Lab. Corp. dissent is 
its failure to recognize the difference between a 
patent ineligible relationship—i.e., that between 
high homocysteine levels and folate and cobalamin 
deficiencies—and a patent eligible process for 
applying that relationship to achieve a useful, 
tangible, and concrete result—i.e., diagnosis of 
potentially fatal conditions in patients. 
. . . . 
. . . [T]he invention does not attempt to claim 
that natural phenomenon.  Instead the patent claims 
a process for assaying a patient’s blood and then 
analyzing the results with a new process that detects 
the life-threatening condition.36 
Claim 13 recites a practical application of the identified 
correlation in the claim preamble—“detecting a deficiency of 
cobalamin or folate”37—and thereby does not preempt all 
implementations and uses of the newly discovered correlation.  
While it would be better claim drafting practice to recite the 
 
 36 In re Bilski, 545 F.3d 943, 1014 (Fed. Cir. 2008) (en banc) (Rader, J., dissenting), 
cert. granted sub nom. Bilski v. Doll, 129 S. Ct. 2735 (2009), argued sub nom. Bilski v. 
Kappos, No. 08-964, 2009 WL 3750776 (Nov. 9, 2009). 
 37 See supra note 33 and accompanying text. 
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diagnostic level or range for the “elevated” homocysteine level in a 
wherein clause in the body of the claim, as in Prometheus 
Laboratory, Inc. v. Mayo Collaborative Services,38 this should not 
detract from the patent eligibility of the subject matter.  Taken as a 
whole, claim 13 defines a specific application of the discovered 
correlation—it requires measuring total homocysteine levels to 
make a specific diagnostic correlation between elevated 
homocysteine levels and deficient cobalamin or folate levels.39  
The claimed method does not foreclose all uses and 
implementations of the correlation such as, for example, using it to 
discover and develop improved treatment methods for cobalamin 
and folate deficiencies or improved methods for measuring other 
biological or chemical markers that correspond to cobalamin or 
folate deficiencies.  In our view, claim 13 properly capitalizes on 
the newly discovered correlation by specific, practical application 
of the correlation to achieve a useful diagnostic process. 
Accurate diagnosis is the touchstone for deciding on any 
treatment regimen in the medical profession, where the guiding 
principle is: “First, do no harm.”40  The availability of incentives to 
encourage inventors to innovate and make diagnostic advances in 
the medical arts would be severely undercut if the entire class of 
these method claims were deemed patent ineligible.  If there is 
concern that physicians and other medical practitioners would be 
liable for infringement of such claims, there is already precedent 
for Congress to step in and protect them.41  Title 35 U.S.C. § 
287(c) exempts medical practitioners from patent infringement 
under § 271(a) and (b) (direct and inducement, but not 
contributory, infringement) for the performance of a certain 
defined “medical activity” that would otherwise constitute an 
 
 38 581 F.3d 1336, 1339 (Fed. Cir. 2009); see U.S. Patent No. 6,355,623 col. 20 ll. 38–
39 (filed Apr. 8, 1999) (issued Mar. 12, 2002).  
 39 U.S. Patent No. 4,940,658 col. 41 ll. 58–65 (filed Nov. 20, 1986) (issued July 10, 
1990).   
 40 This mantra is often ascribed to Hippocrates as part of the Hippocratic Oath, 
however, it is actually derived from a Latin phrase, “Primum non nocere.”  Hippocrates 
came closest to stating these words in his treatise Epidemics. See Howard Markel, “I 
Swear by Apollo”—on Taking the Hippocratic Oath, 350 NEW ENG. J. MED. 2026, 2026–
29 (2004). 
 41 See 35 U.S.C. § 287(c) (2006). 
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infringement.42  This statute was passed after a patent owner tried 
to enforce a patent covering a process for making a certain type of 
surgical incision in the eye during cataract surgery.43  The process 
patent governing a physician’s activity during surgery was 
unquestionably patent eligible,44 and the policy response, after 
heavy lobbying by the American Medical Association, came from 
Congress in the form of the above-referenced exemption.  
Congress chose not to alter the process patent eligibility rules, even 
when it was presented with a perfect opportunity to do so, and we 
submit that the courts should not effect such a result with respect to 
diagnostic method claims, particularly in the absence of a clear 
expression from Congress. 
Claim 13 provides an excellent example to underscore the 
important difference between the low threshold requirements for 
patent eligibility under the Fundamental Principles Exception and 
the much more rigorous requirements for patentability.  Claim 13 
defines patent eligible subject matter, but the patentability of the 
subject matter may still be challenged for other reasons, for 
example: obviousness, non-enablement, or claim overbreadth.  The 
two concepts must be separated and not confused, but confusion is 
exactly what occurred when the court in Parker v. Flook45 
articulated the “post-solution activity” corollary.46  In Flook, the 
 
 42 35 U.S.C. § 287(c)(2)(A) defines “medical activity” as  
the performance of a medical or surgical procedure on a body, but 
shall not include (i) the use of a patented machine, manufacture, or 
composition of matter in violation of such patent, (ii) the practice of a 
patented use of a composition of matter in violation of such patent, or 
(iii) the practice of a process in violation of a biotechnology patent. 
 43 Pallin v. Singer, No. 5:93-202, 1995 WL 608365, at *1 (D. Vt. May 1, 1995). 
 44 In re Bilski, 545 F.3d 943, 988 (Fed. Cir. 2008) (en banc) (Newman, J., dissenting) 
(“We are directed to no authority for the proposition that a new and inventive process 
involving ‘human activity’ has historically been treated differently from other processes; 
indeed most inventions involve human activity.”), cert. granted sub nom. Bilski v. Doll, 
129 S. Ct. 2735 (2009), argued sub nom. Bilski v. Kappos, No. 08-964, 2009 WL 
3750776 (Nov. 9, 2009). 
 45 437 U.S. 584 (1978). 
 46 Id. at 590.  In Flook, the patentee, Dale Flook, applied for a patent on a “Method for 
Updating Alarm Limits.” Id. at 585.  The “alarm limits” were particular numbers between 
which a catalytic converter was determined to be operating normally. Id.  When any of 
the catalytic conversion process variables exceeded a predetermined alarm limit, the 
alarm sounded. Id.  Flook’s patent application described and claimed a method of 
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Supreme Court held that the respondent’s process of applying a 
mathematical algorithm was unpatentable: 
[N]ot because it contains a mathematical algorithm 
as one component, but because once that algorithm 
is assumed to be within the prior art, the 
application, considered as a whole, contains no 
patentable invention.  Even though a phenomenon 
of nature or mathematical formula may be well 
known, an inventive application of the principle 
may be patented.  Conversely, the discovery of such 
a phenomenon cannot support a patent unless there 
is some other inventive concept in its application.47 
While the above-quoted statements are correct, the Court 
improperly conflated the threshold patent eligibility determination 
with the substantive determination of patentability or “inventive 
concept.”  Whether the algorithm or natural phenomenon in 
question is known in the prior art is irrelevant to patent eligibility, 
but quite relevant to the question of patentability.  This type of 
claim dissection into new and old parts was forcefully condemned 
by the Court in Diehr,48 precisely because it confused the threshold 
 
updating alarm limits by utilizing a mathematical algorithm. Id.  Flook’s method was 
identical to previous systems for updating alarm limits except for the use of the 
mathematical algorithm. Id. at 586.  The Patent & Trademark Office Board of Appeals 
sustained the rejection of Flook’s method claims for failing to satisfy the statutory subject 
matter test under Gottschalk v. Benson. Id. at 587; Gottschalk v. Benson, 509 U.S. 63, 67 
(1972).  Flook appealed and the Court of Customs and Patent Appeals (“CCPA”) 
reversed. Flook, 437 U.S. at 587; see also In re Flook, 559 F.2d 21, 23 (C.C.P.A. 1977).  
The CCPA read Benson as applying only to claims that entirely preempt a mathematical 
formula or algorithm, and it held the claims to be patent eligible for examination because 
they recited post-solution activity and did not entirely preempt the formula or algorithm 
used. Flook, 437 U.S. at 587.  The patent claimed only the right to use the algorithm in 
the limited context of the catalytic chemical conversion of hydrocarbons.  The CCPA 
reasoned that since “the mere solution of the algorithm would not constitute infringement 
of the claims, a patent on the method would not preempt the formula.” Id.  The Supreme 
Court granted a writ of certiorari. Id. at 588.  
 47 Flook, 437 U.S. at 594 (emphasis added). 
 48 Diamond v. Diehr, 450 U.S. 175, 188 (1981) (“It is inappropriate to dissect the 
claims into old and new elements and then to ignore the presence of the old elements in 
the analysis.  This is particularly true in a process claim because a new combination of 
steps in a process may be patentable even though all the constituents of the combination 
were well known and in common use before the combination was made.”).  
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question of patent eligibility with the substantive question of 
patentability, obviousness in particular, which can only be 
answered after examination of the patent application and any 
subsequent administrative or litigation challenges.  This confusion, 
also reflected in Justice Breyer’s LabCorp dissent,49 is 
understandable but dangerous because it threatens to restrict the 
statutory category of process patents, contrary to black letter law 
that a new combination of previously well-known process steps 
may be patentable.50  Identification of “prior art” process steps and 
questions of inventive concept or conventional versus nonobvious 
subject matter are part of a patentability analysis;51 they play no 
role in the threshold determination of patent eligible statutory 
subject matter.  Patent eligibility should turn solely on a 
determination of whether the claim as a whole defines a 
fundamental principle and whether it preempts all uses and 
implementations of that principle. 
2. Machine-or-Transformation Analysis 
Viewing LabCorp claim 13 through the prism of Bilski’s 
machine-or-transformation test, rather than the Fundamental 
Principles Exception, adds confusion and complexity.  The inquiry 
focuses on transformation because it is clear that the claimed 
diagnostic process is not tied to any particular machine or 
apparatus. 
The “assaying” step in claim 13 is a necessary data-gathering 
step that allows a physician or other medical practitioners to 
recognize elevated homocysteine levels, which can be correlated to 
a cobalamin or folate deficiency in a sick patient.52  Whether that 
necessary step transforms a blood or urine sample in the process of 
obtaining the data is not necessarily relevant to the question of 
 
 49 See Lab. Corp. of Am. Holdings v. Metabolite Labs. Inc., 548 U.S. 124, 137–38 
(2006) (Breyer, J., dissenting). 
 50 See id. at 136–37.  The emphasis on the assay step as an “unpatented” procedure or 
test in Justice Breyer’s LabCorp dissent is misplaced.  The LabCorp dissent effectively 
ignores and sets aside the “unpatented” assay step, rather than assessing the claimed 
process as a whole as mandated by Diehr. Id. at 129.   
 51 See Flook, 437 U.S. at 594. 
 52 U.S. Patent No. 4,940,658 col. 9 ll. 30–57 (filed Nov. 20, 1986) (issued July 10, 
1990).   
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process patent eligibility.53  Concentrating the analysis on whether 
a transformation occurs and, if so, whether that transformation 
imposes “meaningful limits on the claim’s scope,” is “central to 
the purpose of the claimed process,” or amounts to “insignificant 
extra-solution activity” or mere data-gathering,54 misses the big 
picture and detours the analysis away from the straightforward 
question of whether the claim defines a practical application of the 
correlation.  The use of words like “meaningful,” “central,” 
“insignificant,” and “mere” also add unnecessary complexity, 
subjectivity, and uncertainty to the analysis.  Focusing on 
transformations and the significance or centrality of extra-solution 
activity in determine-and-infer claims, such as claim 13, is another 
way of dissecting and separating claim elements, rather than 
viewing the combination of process steps as a whole to determine 
what, if any, is the practical application of the process. 
These considerations aside, the assay step in claim 13 is 
transformational, and that transformation is necessary and central 
to the claimed diagnostic process.  Dependent claims 15 and 16, 
for example, recite transformational chromatographic techniques to 
be used to measure the homocysteine level in a bodily fluid 
sample, which in turn provides the necessary data for a physician 
to make the diagnostic correlation.55  Yet, one can see how 
different judges could reach very different conclusions about 
whether an assay step is central to a diagnostic method or nothing 
more than mere data-gathering or insignificant extra-solution 
 
 53 See Collins, supra note 34, at 2 (“There is no rational reason to use the tangibility of 
the transformation affected by the determining steps in a determine-and-infer claim as a 
peg on which to hang patent eligibility.”). 
 54 In re Bilski, 545 F.3d 943, 961–63 (Fed. Cir. 2008) (en banc), cert. granted sub 
nom. Bilski v. Doll, 129 S. Ct. 2735 (2009), argued sub nom. Bilski v. Kappos, No. 08-
964, 2009 WL 3750776 (Nov. 9, 2009).  “Each patent examination center, each trial 
court, each panel of this court, will have a blank slate on which to uphold or invalidate 
claims based on whether there are sufficient ‘meaningful limits,’ or whether a 
transformation is adequately ‘central,’ or the ‘significance’ of process steps.” Id. at 994 
(Newman, J., dissenting). 
 55 ’658 Patent col. 42 ll. 7–18.  The chromatographic techniques themselves could 
even be considered special purpose machines that independently satisfy Bilski’s machine-
or-transformation test. See Prometheus Labs., Inc. v. Mayo Collaborative Servs., 581 
F.3d 1336, 1347 (Fed. Cir. 2009).  
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activity that renders a claim patent ineligible.56  The multi-step 
analysis required by Bilski’s transformation test engenders more 
confusion and permits more opportunities for inconsistent, 
subjective judgments on the question of patent eligibility as 
compared to the well-settled Fundamental Principles Exception, 
particularly as articulated by the Court in Diehr.57  Adhering to the 
simpler and more flexible analysis of the Fundamental Principles 
Exception will provide a firmer foundation for more consistent 
judgments of patent eligible subject matter. 
B. Classen Immunotherapies v. Biogen: When Transformation Is 
Not Enough 
Shortly after deciding Bilski and prior to Prometheus, a Federal 
Circuit panel applied the machine-or-transformation test to a 
different type of determine-and-infer claim that did not involve 
diagnostic methods.58  In Classen Immunotherapies, Inc. v. Biogen 
IDEC,59 the district court reviewed claims directed to a method for 
determining a vaccine schedule used to lower the risk of chronic 
immune-mediated diseases in mammals60 and granted summary 
judgment for the defendant on the grounds that Classen’s patents 
were invalid under 35 U.S.C. § 101.61  The Federal Circuit then 
held that the claims failed the machine-or-transformation test 
without providing any analysis.62 
 
56  This scenario is illustrated by the inconsistent decisions of the trial and appellate 
courts in the Prometheus case, discussed infra Part II.C. 
 57 See Diamond v. Diehr, 450 U.S. 175, 185 (1981). 
 58 Classen Immunotherapies, Inc. v. Biogen IDEC, 304 F. App’x 866, 867 (Fed. Cir. 
2008). 
 59 No. WDQ-04-2607, 2006 WL 6161856 (D. Md. Aug. 16, 2006), aff’d, 304 F. App’x 
866 (Fed. Cir. 2008). 
 60 Id. at *5. 
 61 Id. at *6. 
 62 Classen, 304 F. App’x at 866 (“In light of our decision in In re Bilski, we affirm the 
district court’s grant of summary judgment that these claims are invalid under 35 U.S.C. 
§ 101.  Dr. Classen’s claims are neither ‘tied to a particular machine or apparatus’ nor do 
they ‘transform[ ] a particular article into a different state or thing.’  Therefore we 
affirm.” (alteration in original) (internal citations omitted) (quoting In re Bilski, 545 U.S. 
943, 954 (Fed. Cir. 2008) (en banc), cert. granted sub nom. Bilski v. Doll, 129 S. Ct. 
2735 (2009), argued sub nom. Bilski v. Kappos, No. 08-964, 2009 WL 3750776 (Nov. 9, 
2009))). 
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Classen may have been correctly decided, but we do not 
believe that application of the machine-or-transformation test led 
the court to the correct result.  Claim 1 of U.S. Patent No. 
5,723,283 (the “’283 patent”), the principal claim at issue in 
Classen, reads: 
A method of determining whether an immunization 
schedule affects the incidence or severity of a 
chronic immune-mediated disorder in a treatment 
group of mammals, relative to a control group of 
mammals, which comprises immunizing mammals 
in the treatment group of mammals with one or 
more doses of one or more immunogens, according 
to said immunization schedule, and comparing the 
incidence, prevalence, frequency or severity of said 
chronic immune-mediated disorder or the level of a 
marker of such a disorder, in the treatment group, 
with that in the control group.63 
The first step in the claimed process recites “immunizing” 
subjects in a treatment group of mammals; the second step recites 
“comparing” therapeutic affect data from treatment and control 
groups.64  In line with claim 13 in LabCorp, claim 1 of the ’283 
patent plainly follows a type of determine-and-infer template but 
without the specificity or particularity of LabCorp claim 13.65  The 
“comparing” step here,66 as in LabCorp claim 13, is directed to a 
mental activity that, under Bilski, does not qualify as 
transformational.67  The “immunizing” step, however, is directed 
to altering subject mammals from an initial state (i.e., susceptible 
to a pathogen) into a different state (i.e., immune to a pathogen).68  
 
 63 U.S. Patent No. 5,723,283 col. 51 ll. 50–60 (filed May 31, 1995) (issued Mar. 2, 
1998). 
 64 Id. 
 65 Compare id. at col. 51 ll. 50–60, with U.S. Patent No. 4,940,658 col. 41 ll. 58–65 
(filed Nov. 20, 1986) (issued July 10, 1990).   
 66 ’283 Patent col. 51 ll. 57–60; see also Classen, 2006 WL 6161856, at *5. 
 67 See Bilski, 545 F.3d at 965. 
 68 See ’283 Patent col. 51 ll. 54–56; Warren Woessner & Tania Shapiro-Barr, Federal 
Circuit Applies Bilski Standard in Classen, PAT. STRATEGY & MGMT., Mar. 2009, at 1, 4 
(“The step of ‘immunizing mammals,’ as recited in the Classen claim, entails the 
transformation of mammals from a nonimmune state to an immune state.”). 
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As several commentators note, this sort of activity plainly qualifies 
as transformational under Bilski.69  Of course, it must still be 
determined whether that transformation is “central” to the claimed 
process and not “insignificant extra-solution activity” or “mere 
data-gathering.”70  The court in Classen apparently concluded that 
the immunizing step was not central to the claimed process or 
constituted mere data-gathering; otherwise it is difficult to fathom 
the basis for the court’s decision.  While the basis for the court’s 
conclusion is not expressed, it is quite plausible that a different 
court might conclude otherwise, reasoning that the preamble 
language defines a particular patent eligible use and the 
immunization of the treatment group is central to a method for 
determining an optimal immunization schedule to prevent 
immune-mediated disorders. 
It is worth recalling that the Bilski majority proffered the 
machine-or-transformation test as a proxy for the Fundamental 
Principles Exception because the latter inquiry was “hardly 
straightforward.”71  But it begs the question: What is 
straightforward about determining whether a particular 
transformation is central to a claimed diagnostic or treatment 
optimization process; or whether it constitutes mere data-
gathering; or whether it constitutes insignificant extra-solution 
activity?  In our view, the difficulty of answering these questions is 
illustrated in Classen.  In contrast, the Fundamental Principles 
Exception requires determining whether the claim particularizes an 
application of a fundamental principle (natural law, natural 
phenomenon, and/or abstract idea) so as not to preempt all uses of 
that principle.72 
Analyzed under the Fundamental Principles Exception, the 
hallmark of claim 1 in Classen appears to be its abstractness and 
lack of particularity.  The claim recites the process steps of 
performing a medical procedure (immunization according to an 
 
 69 See Holman, supra note 10, at 18; Woessner & Shapiro-Barr, supra note 68, at 4. 
 70 Bilski, 545 F.3d at 962. 
 71 Id. at 954. 
 72 See Diamond v. Diehr, 450 U.S. 175, 203 (1981); Parker v. Flook, 437 U.S. 584, 
599 (1978); Gottschalk v. Benson, 409 U.S. 63, 71 (1972); see also Bilski, 545 F.3d at 
1011 (Rader, J., dissenting). 
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undefined schedule) on individuals in an experimental treatment 
group and comparing the incidence (or severity) of a class of 
disorders in the treatment group to the incidence (or severity) in a 
control group.73  The claimed process embodies a general 
application of the scientific method to a class of chronic immune-
mediated disorders.74  The process is an abstract technique or 
algorithm for conducting research that mandates varying the 
conditions in an experimental treatment group with respect to a 
control group and observing the comparative effects.75  Although 
the claim is drawn to the field of vaccine scheduling studies for 
chronic immune-mediated disorders, there is no particular 
application claimed.  Because of that lack of particularity, claim 1 
constitutes an impermissible attempt to preempt the use of the 
scientific method in the field of vaccine scheduling studies for 
chronic immune-mediated disorders.  The claim does not apply the 
scientific method to prescribe or optimize a particular vaccine 
schedule that entails less risk of a particular chronic immune-
mediated disorder in a particular subject group.76  If it did so, that 
would reduce the claim’s preemptive footprint to a specific 
application in the field of use.  As it is, however, the claim is 
drawn to a general application of the scientific method in research 
involving all possible vaccination schedules vis-à-vis all possible 
immune-mediated disorders in all kinds of mammals.  We note that 
the district court applied the Fundamental Principles Exception in 
its opinion granting summary judgment of invalidity: “Although 
articulated as a process, the [’]283 patent does not claim a specific 
technique or technical process of testing vaccine safety.  Instead, 
 
 73 ’283 Patent col. 51 ll. 50–60. 
 74 See id. at cols. 51–54. 
 75 See id. 
76 Indeed, Dr. Classen purportedly discovered  
that when one or more immunogens, in a pharmaceutically acceptable 
composition, is first administered at an early age (typically prior to 42 
days of age), it can substantially decrease the incidence, frequency, 
prevalence or severity of, or prevent, at least one chronic immune 
mediated disorder, and/or a surrogate marker thereof. 
Id. at col. 7 ll. 35–41.  However, Claim 1 fails to recite a vaccination schedule prior to 42 
days of age, instead attempting to claim the general investigative method upon which the 
purported discovery was based to foreclose all other inquiries into optimal vaccination 
schedules in all mammals. 
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the [’]283 patent describes only a general inquiry of whether the 
proposed correlation between an immunization schedule and the 
incidence of chronic disorders exists.”77  In Classen, we submit, 
application of the Fundamental Principles Exception is a more 
straightforward test and yields the correct result with greater clarity 
and certainty than application of the machine-or-transformation 
test. 
C. Patent Eligibility of the Prometheus Claims 
The Prometheus case, which we also believe was correctly 
decided, illustrates the difficulties inherent in the machine-or-
transformation test as applied to method claims in the emerging 
field of personalized medicine.  Prometheus is the sole and 
exclusive licensee of patents claiming methods for determining the 
proper dosage of thiopurine drugs, which are used for treating both 
gastrointestinal and non-gastrointestinal autoimmune diseases.78  
These drugs include 6-mercaptopurine (“6-MP”) and azathiopurine 
(“AZA”), a pro-drug that converts to 6-MP, which are used to treat 
inflammatory bowel diseases (“IBD”) such as Crohn’s disease and 
ulcerative colitis.79  6-MP is broken down by the body into various 
6-MP metabolites, including 6-methyl-mercaptopurine (“6-MMP”) 
and 6-thioguanine (“6-TG”).80  The patents involve determining 
the concentration of these two metabolites in sick patients. 
6-MP and AZA have been used for years to treat autoimmune 
diseases, but non-responsiveness and drug toxicity may complicate 
treatment in some patients.81  The patents, therefore, claim 
methods that seek to optimize therapeutic efficacy while 
minimizing toxic side effects.  Claim 1 of the ’623 patent is 
representative: 
A method of optimizing therapeutic efficacy for 
treatment of an immune-mediated gastrointestinal 
disorder, comprising: (a)  administering a drug 
 
 77 Classen Immunotherapies, Inc. v. Biogen IDEC, No. WDQ-04-2607, 2006 WL 
6161856, at *5 (D. Md. Aug. 16, 2006), aff’d, 304 F. App’x 866 (Fed. Cir. 2008). 
 78 U.S. Patent No. 6,355,623 (filed Apr. 8, 1999) (issued Mar. 12, 2002). 
 79 Id. at col. 1 ll. 41–44. 
 80 Id. at col. 1 ll. 45–48. 
 81 Id. 
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providing 6-thioguanine to a subject having said 
immune-mediated gastrointestinal disorder; and (b)  
determining the level of 6-thioguanine in said 
subject having said immune-mediated 
gastrointestinal disorder, wherein the level of 6-
thioguanine less than about 230 pmol per 8x108 red 
blood cells indicates a need to increase the amount 
of said drug subsequently administered to said 
subject and wherein the level of 6-thioguanine 
greater than about 400 pmol per 8x108 red blood 
cells indicates a need to decrease the amount of said 
drug subsequently administered to said subject.82 
Emphasizing that the Prometheus patent contains “method of 
treatment” claims, with particular emphasis on the preamble 
language of “optimizing therapeutic efficacy” and “reducing 
toxicity,” the Federal Circuit reversed the district court and found 
the claims patent eligible.83  There was no serious dispute between 
the parties that both the administration of a drug providing 6-TG 
and the determination of the 6-TG level in a patient resulted in 
transformations, either in the human body or in a blood sample.84  
Instead, the critical issue was whether those steps constituted 
insignificant extra-solution activity, mere data-gathering or 
something more.85  The court, however, strained to explain its 
rationale for distinguishing the administration and determining 
steps from mere data-gathering steps, declaring that these steps are 
“central” to the purpose of the claims because “the administering 
and determining steps are part of a treatment protocol, and they are 
transformative.”86  In our view, the mandatory machine-or-
transformation test caused the court to strain unnecessarily to try to 
fit a square peg into a round hole by arguing that the claims are 
methods of treatment.87  The claims do not use traditional language 
 
 82 Id. at col. 20 ll. 10–25 (emphasis added). 
 83 Prometheus Labs., Inc. v. Mayo Collaborative Servs., 581 F.3d 1336, 1341 (Fed. 
Cir. 2009).  The district court found that the administration and determining steps 
amounted to mere data-gathering steps and held the claims to be patent ineligible. Id. 
 84 Id. at 1347. 
 85 Id. 
 86 Id. (emphasis added). 
 87 Id. at 1346. 
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such as “administering a therapeutically effective amount of 6-
TG,” which one would expect to see in a method of treatment 
claim.  Moreover, as the district court pointed out below, the 
“wherein” clauses do not require any actual change in dosage to 
optimize the therapeutic efficacy or to reduce toxicity of the 
treatment.88  It would have been simpler and more effective had the 
court applied the analysis required by the Fundamental Principles 
Exception. 
The court articulated its most compelling argument for patent 
eligibility in an insightful application of the Fundamental 
Principles Exception: 
[T]he claims do not preempt natural processes; they 
utilize them in a series of specific steps. . . . The 
inventive nature of the claimed methods stems not 
from preemption of all use of these natural 
processes, but from the application of a natural 
phenomenon in a series of transformative steps 
comprising particular methods of treatment.89 
The natural phenomenon at issue is the ability of the human 
body to metabolize a drug to 6-TG.90  It is not the claimed 
correlation between a metabolite level generated from 
administration of a synthetic drug and an optimal therapeutic or 
non-toxic dose.  The claimed process utilizes the naturally 
occurring metabolic function to generate measurable metabolite 
levels that can be compared to optimal levels for optimizing 
therapeutic efficacy or reducing toxicity.  The patent does not 
claim the naturally occurring metabolic function itself.  The 
correlation defined in the wherein clauses, with specific 
concentrations of 6-TG recited, is the practical application of a 
treatment optimization process for a sick patient as recited in the 
claim preamble.91  Like the determine-and-infer claims of 
LabCorp,92 this is all that should be required for patent eligibility, 
 
 88 Id. at 1341. 
 89 Id. at 1349. 
 90 See U.S. Patent No. 6,355,623 col. 4 ll. 60–64 (filed Apr. 8, 1999) (issued Mar. 12, 
2002) (stating that both 6-MP and AZA can be metabolized to 6-TG). 
 91 Id. at col. 2 ll. 16–18. 
 92 See supra note 34 and accompanying text. 
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freed from the additional restraints of Bilski’s machine-or-
transformation test. 
D. Association for Molecular Pathology v. United States Patent & 
Trademark Office: Omitting the Determination Step 
Inspired by the rulings in Bilski and Classen, the plaintiffs in 
Association for Molecular Pathology v. United States Patent & 
Trademark Office93 invoked § 101, inter alia, to challenge a group 
of patents owned by Myriad Genetics.94  The patents cover breast 
and ovarian cancer-susceptibility genes BRCA1/BRCA2, as well 
as diagnostic and therapeutic screening methods utilizing those 
genes.95  According to plaintiffs, certain claims in the patents 
violate § 101 under the Fundamental Principles Exception because 
the claims cover “products of nature, laws of nature and/or natural 
phenomena, and abstract ideas or basic human knowledge or 
thought.”96  The court recently granted summary judgment of 
invalidity and an appeal is pending.97 
Claim 1 of U.S. Patent No. 5,709,999 (the “’999 patent”) is 
representative of the diagnostic method claims at issue in the case: 
A method for detecting a germline alteration in a 
BRCA1 gene, said alteration selected from the 
group consisting of the alterations set forth in 
Tables 12A, 14, 18 or 19 in a human which 
comprises analyzing a sequence of a BRCA1 gene 
or BRCA1 RNA from a human sample or analyzing 
a sequence of BRCA1 cDNA made from mRNA 
from said human sample with the proviso that said 
germ line alteration is not a deletion of 4 
 
 93 No. 09 Civ. 4515, 2010 WL 1233416 (S.D.N.Y. Apr. 5, 2010).   
 94 Id. at *1.   
 95 Id.  
 96 Id. 
97  Id.  Applying Bilski’s machine-or-transformation test, the court struck down all of 
the method claims at issue in the suit. See id. at *46–50.  More suprisingly, the court also 
invalidated the composition claims covering isolated DNA corresponding to the 
BRCA1/BRCA 2 genes as “not markedly different” than products of nature. See id. at 
*41–46.  
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nucleotides corresponding to base numbers 4184-
4187 of SEQ ID NO: 1.98 
Strikingly, and unlike the claims in LabCorp, Classen or 
Prometheus, this claim recites only an “analyzing” step without 
further limitation.  Although there is no doubt that extensive 
handling and manipulation of genetic material needs to be 
performed prior to the claimed “analyzing” step, and that such 
activity would likely satisfy Bilski’s transformation test, those 
implicit manipulations are not recited as part of the claimed 
process.  In other words, the claim departs from the determine-and-
infer template by omitting altogether the “determine” step.  The 
court characterizes claim 1 of the ’999 patent as follows: “[w]hile 
the purpose of the claimed method is, for example, to ‘detect a 
germline alteration in a BRCA1 gene,’ the method actually 
claimed is ‘analyzing a sequence of a BRCA1 gene.”’99 
Because claim 1 of the ’999 patent, as a whole, is directed to a 
purely mental process, the claimed process should not withstand 
scrutiny under the Fundamental Principles Exception.100 The claim 
also fails the machine-or-transformation test.  The “analyzing” step 
is not tied to a particular machine nor does it transform a particular 
article into a different state or thing.  There is no claimed assay or 
“determining” step to determine the sequence of a BRCA1 gene in 
a human sample, although such a step is implicit in the claim.  The 
claim does not require the physical transformation of a tissue 
sample or any other physical transformation.  Therefore, 
 
 98 U.S. Patent No. 5,709,999 col. 161 ll. 17–25 (filed June 7, 1995) (issued Jan. 20, 
1998) (emphasis added). 
 99 See Ass’n for Molecular Pathology, 2010 WL 1233416, at *48 (internal citations 
omitted) (emphasis in original) (citing ’999 Patent col. 161 ll. 17–18, 20–21). 
 100 In Bilski, the majority characterized the “hedging” claim at issue as directed to a 
“purely mental process of performing requisite mathematical calculations without the aid 
of a computer or any other device” followed by an insignificant post-solution step. In re 
Bilski, 545 F.3d 943, 965 (Fed. Cir. 2008) (en banc), cert. granted sub nom. Bilski v. 
Doll, 129 S. Ct. 2735 (2009), argued sub nom. Bilski v. Kappos, No. 08-964, 2009 WL 
3750776 (Nov. 9, 2009).  Quoting In re Comiskey, 499 F.3d 1365 (Fed. Cir. 2007), which 
struck down claims directed to a process for arbitrating a particular kind of commercial 
dispute, the majority observed that “claims to such an ‘application of [only] human 
intelligence to the solution of practical problems’ is no more than a claim to a 
fundamental principle.” Bilski, 545 F.3d at 965 (alteration in original) (quoting Comiskey, 
499 F.3d at 1379). 
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application of the machine-or-transformation test should not save 
this claim under § 101. 
In contrast, claim 20 of U.S. Patent No. 5,747,282 (the “’282 
patent”) does not omit the “determine” step in the determine-and-
infer template and therefore requires a closer analysis under § 101.  
Claim 20 recites: 
A method for screening potential cancer 
therapeutics which comprises: growing a 
transformed eukaryotic host cell containing an 
altered BRCA1 gene causing cancer in the presence 
of a compound suspected of being a cancer 
therapeutic, growing said transformed eukaryotic 
host cell in the absence of said compound, 
determining the rate of growth of said host cell in 
the presence of said compound and the rate of 
growth of said host cell in the absence of said 
compound and comparing the growth rate of said 
host cells, wherein a slower rate of growth of said 
host cell in the presence of said compound is 
indicative of a cancer therapeutic.101 
Unlike claim 1 of the ’999 patent, this claim is not directed 
solely to a mental process or a naturally occurring phenomenon.  
The first two steps require “growing” a particular type of cell in the 
presence or absence of a suspected cancer therapeutic; the last two 
steps require the mental steps of “determining” and “comparing” 
growth rates.102  This claim’s structure leads to the question of 
whether it is closer to the claim in Classen or the claim in 
Prometheus.103   
In our view, claim 20 in the ’282 patent is a practical 
application of screening potential therapies for the types of breast 
 
 101 U.S. Patent No. 5,747,282 col. 156 ll. 15–27 (filed June 7, 1995) (issued May 5, 
1998) (emphasis added). 
 102 Id.  
103  The district court has concluded the former, disparaging the recited transformative 
steps as “nothing more than preparatory, data-gathering steps to obtain growth rate 
information” and stating that the transformative steps “do not render the claimed mental 
process patentable under § 101.” Ass’n for Molecular Pathology, 2010 WL 1233416, at 
*50.   
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and ovarian cancers attributable to the altered BRCA1 gene.104  
The growth rates of transformed eukaryotic host cells are not 
natural phenomena, they are process steps required for trying to 
identify potential compounds that can treat particular diseases.105  
The process may be obvious or imperfectly enabled, but it should 
not be deemed patent ineligbile. 
Like Classen, the claim limits application of the principle to a 
field of use, which is cancer therapeutics.106  Unlike Classen, 
however, the claim does not attempt to preempt all uses of the 
principle in that field of use, but is instead limited to a specific 
application involving particular gene sequences responsible for 
causing particular types of cancer.107  As the majority in Bilski 
acknowledged, the Fundamental Principles Exception is essentially 
an inquiry into the scope of the exclusion effected by the claim.108  
Here claim 20 of the ’282 patent is drawn to a specific application 
of the scientific method to screen potential cancer therapeutics 
with respect to a particular gene sequence.  The claim does not 
preempt all uses of the principle in all fields or even in the single 
field of cancer therapeutics. 
Application of the machine-or-transformation test would be 
less straightforward and could possibly lead to a different 
conclusion, unfairly restricting patent eligibility for claim 20 of the 
’282 patent and other claims of its ilk (as illustrated by the district 
court decision).  The claimed screening process is not tied to a 
particular machine or apparatus.109  Thus, the issue is whether the 
 
 104 See ’282 Patent col. 156 ll. 15–27.  
 105 Id. 
 106 See id. at col. 1 ll. 19–23. 
 107 Id. at col. 1 ll. 24–40. 
 108 In re Bilski, 545 F.3d 943, 953 (Fed. Cir. 2008) (en banc), cert. granted sub nom. 
Bilski v. Doll, 129 S. Ct. 2735 (2009), argued sub nom. Bilski v. Kappos, No. 08-964, 
2009 WL 3750776 (Nov. 9, 2009). 
 109 The Bilski test requires the claimed process to be tied to a particular machine or 
apparatus.  While it has been argued that this “tying” requirement should not be limited 
only to machines but include other categories of statutory subject matter such as 
compositions of matter, see Prometheus Labs., Inc. v. Mayo Collaborative Servs., 581 
F.3d 1336, 1343 (Fed. Cir. 2009) (“In addition, Prometheus contends that Bilski’s use of 
‘machine’ in its machine-or-transformation test must be read as shorthand for all 
patentable subject matter, including compositions of matter.”), the Court has not 
expressly ruled on that issue.  If the tying requirement allows for tying the claimed 
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“growing” steps are transformational and, if so, whether the 
transformation is central to the claimed process or insignificant 
extra-solution activity.110  The “growing” steps essentially require 
an in vitro experiment whereby eukaryotic cells containing the 
BRCA1 gene are cultured in the presence and absence of a 
suspected cancer therapeutic agent.111  This kind of activity 
qualifies as a transformation under Bilski, particularly in view of 
Prometheus, because it involves altering a particular article (a 
eukaryotic cell containing a BRCA1 gene) from an initial state (a 
single or few cells) to a different state (a larger population of 
cells).112  However, some could argue that cells naturally divide 
(“grow”) without any human intervention and the essentially 
passive act of providing a proper artificial medium and conditions 
to allow them to do so in vitro is akin to watering a plant in the 
presence of adequate sunlight.  If it is at all doubtful that the latter 
activity is transformational, then it is doubtful the former activity is 
too.  In any event, the outcome of a machine-or-transformation 
analysis of claim 20 of the ’282 patent appears to be more 
uncertain than under the Fundamental Principles Exception and 
could unfairly exclude this important screening method advance 
from the category of patent eligible subject matter under § 101. 
CONCLUSION 
The foregoing claims analysis demonstrates that the machine-
or-transformation test of Bilski is not particularly well-suited to 
assessing the types of diagnostic and genetic screening methods 
that are increasingly utilized in the area of personalized medicine.  
Under that test, it is plausible that a claim such as LabCorp’s claim 
13 could be excluded as patent ineligible even though application 
 
process to a particular composition of matter, then claim 1 of the ’282 patent more easily 
meets the test. Bilski, 545 F.3d at 954. 
 110 At first blush, the use of the word “transformed” in the claim may lead some 
immediately to assume that some kind of transformation is involved in the “growing” 
steps of the claimed process, but that would be a mistake.  In the context of the claim, the 
process of transforming a eukaryotic cell with an altered BRCA1 gene is not recited as a 
step in the claim.  The question whether a transformation occurs as part of a claimed 
process must be determined only with respect to the recited steps. 
 111 ’282 Patent col. 1 l. 61–col. 26 l. 5. 
 112 Id. at col. 156 ll. 15–23. 
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of the Fundamental Principles Exception should lead to the 
opposite conclusion.  The claims at issue in Prometheus and claim 
20 of the ’282 patent in the Myriad Genetics case reflect similar 
uncertainties.  Conversely, applying the machine-or-transformation 
test to a claim such as Classen’s, it is plausible that a court could 
find patent eligibility, even though we believe application of the 
Fundamental Principles Exception should dictate otherwise.  The 
uncertainty principally lies in assessing whether a particular 
transformation satisfies the “insignificant extra-solution activity” 
corollary of the machine-or-transformation test.  In our view, 
Bilski’s transformation analysis focuses on the wrong question for 
diagnostic and screening methods and unnecessarily complicates 
what should be a straightforward assessment of whether patent 
eligible subject matter is entitled to be examined for compliance 
with the requirements for patentability.  To avoid this kind of 
uncertainty, especially in the increasingly important areas of 
medical diagnostics and personalized medicine, the Supreme Court 
should reemphasize the primacy of the well-settled Fundamental 
Principles Exception standard for determining patent eligibility of 
process claims and reject the mandatory, exclusive applicability of 
the machine-or-transformation test. 
